10X1000-TECH
5.3.2024 14:28:31 CET | Business Wire | Press release
The Global Digital Talent Community 10x1000 Tech for Inclusion (“10x1000”) and FINOLAB, a Tokyo-based fintech office and business community, have entered into a collaborative effort to enhance digital capacity and drive digital economic growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305260615/en/
The Global Digital Talent Community 10x1000 Tech for Inclusion (“10x1000”) and FINOLAB have entered into a collaborative effort to enhance digital capacity and drive digital economic growth. (Photo: Business Wire)
Pursuant to a signed Memorandum of Understanding (MoU), FINOLAB will collaborate with 10x1000 to identify and invite qualified participants through its network of member institutions, partners, affiliates, and other stakeholders to participate in the learning programs provided by 10x1000. Participants will be afforded the opportunity to serve as both learners and industry experts.
Additionally, the two organizations will work together to develop learning content that highlights and promotes the digital landscape and opportunities in Japan and drive knowledge sharing through their respective networks.
The MoU was signed by Jennifer Tan, Program Head for 10x1000 Tech for Inclusion, and Makoto Shibata, Head of FINOLAB and Chief Community Officer at FINOLAB. The signing ceremony was witnessed by Sopnendu Mohanty, Chief Fintech Officer at the Monetary Authority of Singapore, Leiming Chen, Chief Sustainability Officer of Ant International and Senior Vice President at Ant Group, and Chie Ito, Chief Executive Officer of FINOLAB.
“We are honored to join hands with FINOLAB to extend the network of 10x1000 in terms of both learners and lecturers, which will benefit the community profoundly. This collaboration marks a pivotal moment in our journey towards cultivating a vibrant and inclusive talent development ecosystem, where innovation knows no boundaries,” said Ms. Tan.
“Our members would benefit immensely from the knowledge accumulation of 10x1000 and we may also be able to contribute our experiences in Japan to the 10x1000 community members. The collaboration would be an appropriate opportunity for all of us to appreciate the true value of open innovation,” commented Mr. Shibata.
By the year 2023, 10x1000 has certified a total of 6,243 learners from over 100 countries and regions. The Philippines, Indonesia, Thailand, Bangladesh, and Nigeria were the top five countries from which most learners came. Of the certified learners, females accounted for 49% of the total learner base. It is noteworthy that the certified learners represent more than 2,000 organizations, and nearly 80% of them are micro, small, or medium-sized enterprises (MSMEs).
About 10x1000 Tech for Inclusion
10x1000 Tech for Inclusion is an open and global learning community that enables learners to become drivers of digital economic growth. Its mission is to nurture and inspire at least 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
About FINOLAB
FINOLAB is a membership business community and an office space located in the heart of international financial district in Tokyo to promote FinTech ecosystem and open innovation. Launched in Feb. 2016 by Mitsubishi Estate and Dentsu Group as the first FinTech Center in Japan, it consists of stakeholders, including startups, corporates, and regulators.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305260615/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom